• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异源 Ad26/Ad5 腺病毒载体疫苗诱导产生了具有强大 Fc 活性的 SARS-CoV-2 特异性抗体反应。

Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities.

机构信息

Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

James J. Peters VA Medical Center, Bronx, NY, United States.

出版信息

Front Immunol. 2024 May 8;15:1382619. doi: 10.3389/fimmu.2024.1382619. eCollection 2024.

DOI:10.3389/fimmu.2024.1382619
PMID:38779671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11109367/
Abstract

INTRODUCTION

Antibodies against the SARS-CoV-2 spike protein are a critical immune determinant for protection against the virus. While virus neutralization is a key function of spike-specific antibodies, antibodies also mediate Fc-dependent activities that can play a role in protection or pathogenesis.

METHODS

This study characterized serum antibody responses elicited after two doses of heterologous adenovirus-vectored (Ad26/ Ad5) vaccines.

RESULTS

Vaccine-induced antibody binding titers and Fc-mediated functions decreased over six months, while neutralization titers remained stable. Comparison of antibody isotypes elicited after Ad26/Ad5 vs. LNP-mRNA vaccination and after infection showed that anti-spike IgG1 were dominant and produced to high levels in all groups. The Ad26/Ad5 vaccines also induced IgG4 but not IgG2 and IgG3, whereas the LNP-mRNA vaccines elicited a full Ig spectrum (IgM, IgG1-4, IgA1-2). Convalescent COVID-19 patients had mainly IgM and IgA1 alongside IgG1. Despite these differences, the neutralization potencies against early variants were similar. However, both vaccine groups had antibodies with greater Fc potencies of binding complement and Fcg receptors than the COVID-19 group. The Ad26/Ad5 group also displayed a greater potency of RBD-specific antibody-mediated cellular phagocytosis.

DISCUSSION

Antibodies with distinctive quality were induced by different vaccines and infection. The data imply the utility of different vaccine platforms to elicit antibody responses with fine-tuned Fc activities.

摘要

简介

针对 SARS-CoV-2 刺突蛋白的抗体是针对该病毒的保护性免疫决定因素。虽然病毒中和是刺突特异性抗体的关键功能,但抗体也介导 Fc 依赖性活性,这些活性可能在保护或发病机制中发挥作用。

方法

本研究对两剂异源腺病毒载体(Ad26/Ad5)疫苗引起的血清抗体反应进行了描述。

结果

疫苗诱导的抗体结合滴度和 Fc 介导的功能在六个月内下降,而中和滴度保持稳定。Ad26/Ad5 与 LNP-mRNA 疫苗接种后和感染后诱导的抗体同种型的比较表明,抗刺突 IgG1 是优势抗体,在所有组中均产生高水平。Ad26/Ad5 疫苗还诱导 IgG4,但不诱导 IgG2 和 IgG3,而 LNP-mRNA 疫苗则诱导完整的 Ig 谱(IgM、IgG1-4、IgA1-2)。恢复期 COVID-19 患者主要产生 IgM 和 IgA1 以及 IgG1。尽管存在这些差异,但针对早期变异体的中和效力相似。然而,与 COVID-19 组相比,两组疫苗接种者的抗体均具有更高的结合补体和 Fcg 受体的 Fc 效力。Ad26/Ad5 组还显示出针对 RBD 特异性抗体介导的细胞吞噬作用的更高效力。

讨论

不同的疫苗和感染诱导了具有独特质量的抗体。这些数据表明,不同的疫苗平台可用于诱导具有精细 Fc 活性的抗体反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/85aa28f3d1e1/fimmu-15-1382619-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/67c6d2c341da/fimmu-15-1382619-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/5029917dc105/fimmu-15-1382619-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/346dc2f2c3d1/fimmu-15-1382619-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/c0b67626028b/fimmu-15-1382619-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/7373ae7188a4/fimmu-15-1382619-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/d1b68396b07e/fimmu-15-1382619-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/78e70d0e79ea/fimmu-15-1382619-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/85aa28f3d1e1/fimmu-15-1382619-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/67c6d2c341da/fimmu-15-1382619-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/5029917dc105/fimmu-15-1382619-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/346dc2f2c3d1/fimmu-15-1382619-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/c0b67626028b/fimmu-15-1382619-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/7373ae7188a4/fimmu-15-1382619-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/d1b68396b07e/fimmu-15-1382619-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/78e70d0e79ea/fimmu-15-1382619-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951b/11109367/85aa28f3d1e1/fimmu-15-1382619-g008.jpg

相似文献

1
Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities.异源 Ad26/Ad5 腺病毒载体疫苗诱导产生了具有强大 Fc 活性的 SARS-CoV-2 特异性抗体反应。
Front Immunol. 2024 May 8;15:1382619. doi: 10.3389/fimmu.2024.1382619. eCollection 2024.
2
Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals.检测接种和感染个体的血浆和唾液中针对 SARS-CoV-2 的抗体反应。
Front Immunol. 2021 Dec 20;12:759688. doi: 10.3389/fimmu.2021.759688. eCollection 2021.
3
A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.单次皮下或鼻内接种基于腺病毒的 SARS-CoV-2 疫苗可在小鼠中诱导强烈的体液和细胞免疫应答。
Eur J Immunol. 2021 Jul;51(7):1774-1784. doi: 10.1002/eji.202149167. Epub 2021 May 6.
4
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies.鼻腔内接种腺病毒载体奥密克戎疫苗诱导的鼻免疫球蛋白 A 比血清抗体具有更高的中和效力。
Signal Transduct Target Ther. 2024 Jul 22;9(1):190. doi: 10.1038/s41392-024-01906-0.
5
Establishment of human post-vaccination SARS-CoV-2 standard reference sera.建立人接种 SARS-CoV-2 疫苗后标准参考血清。
J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.
6
Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults.成人中AdCLD-CoV19-1疫苗的剂量依赖性血清学分析
mSphere. 2025 Jan 28;10(1):e0099824. doi: 10.1128/msphere.00998-24. Epub 2024 Dec 26.
7
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.接种 BBIBP-CorV 作为基础免疫后加强接种异源 Ad26.COV2.S 对 SARS-CoV-2 感染的效果:一项 1 年随访的 1/2 期开放标签试验。
Vaccine. 2024 Jul 25;42(19):3999-4010. doi: 10.1016/j.vaccine.2024.05.010. Epub 2024 May 13.
8
The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.mRNA-1273 疫苗诱导对 SARS-CoV-2 的交叉变体抗体反应,具有预先存在免疫个体和无预先存在免疫个体的不同特征。
Front Immunol. 2021 Sep 3;12:737083. doi: 10.3389/fimmu.2021.737083. eCollection 2021.
9
Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.通过 SARS-CoV-2 刺突受体结合域 Fc 融合蛋白在小鼠中增强诱导强效中和抗体。
Vaccine. 2020 Oct 27;38(46):7205-7212. doi: 10.1016/j.vaccine.2020.09.058. Epub 2020 Sep 22.
10
Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.腺病毒载体二价疫苗在小鼠模型中对野生型 SARS-CoV-2 和奥密克戎变异株的免疫原性。
Vaccine. 2024 Feb 27;42(6):1292-1299. doi: 10.1016/j.vaccine.2024.01.073. Epub 2024 Jan 30.

本文引用的文献

1
Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination.接种 SARS-CoV-2 疫苗后抗体 Fc 效应功能的衰减和增强。
Nat Commun. 2023 Jul 13;14(1):4174. doi: 10.1038/s41467-023-39189-8.
2
Functional Characteristics of Serum Anti-SARS-CoV-2 Antibodies against Delta and Omicron Variants after Vaccination with Sputnik V.接种卫星 V 后血清抗 SARS-CoV-2 抗体针对德尔塔和奥密克戎变异株的功能特征。
Viruses. 2023 Jun 10;15(6):1349. doi: 10.3390/v15061349.
3
Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines.
混合免疫扩大了 mRNA 和基于载体的 SARS-CoV-2 疫苗的功能性体液免疫记忆。
Cell Rep Med. 2023 May 16;4(5):101048. doi: 10.1016/j.xcrm.2023.101048. Epub 2023 Apr 25.
4
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection.超越中和作用:Fc 依赖性抗体效应功能在 SARS-CoV-2 感染中的作用。
Nat Rev Immunol. 2023 Jun;23(6):381-396. doi: 10.1038/s41577-022-00813-1. Epub 2022 Dec 19.
5
Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients.区分老年患者中住院与门诊COVID-19病例的免疫特征。
iScience. 2022 Dec 22;25(12):105608. doi: 10.1016/j.isci.2022.105608. Epub 2022 Nov 16.
6
Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection.血清 Fc 介导的单核细胞吞噬活性在 SARS-CoV-2 无症状和轻度症状感染后数月内保持稳定。
Microbiol Spectr. 2022 Dec 21;10(6):e0183722. doi: 10.1128/spectrum.01837-22. Epub 2022 Nov 14.
7
Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern.基于微阵列技术的 SARS-CoV-2 变异株疫苗诱导抗体应答谱分析:关注变异株和感兴趣变异株。
Int J Mol Sci. 2022 Oct 30;23(21):13220. doi: 10.3390/ijms232113220.
8
Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina.在阿根廷,机构内老年人接种 COVID-19 疫苗 6 个月后的体液反应和中和能力。
Front Immunol. 2022 Sep 26;13:992370. doi: 10.3389/fimmu.2022.992370. eCollection 2022.
9
A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.SARS-CoV-1 与 SARS-CoV2 的比较:当前 COVID-19 疫苗的最新进展。
Daru. 2022 Dec;30(2):379-406. doi: 10.1007/s40199-022-00446-8. Epub 2022 Sep 2.
10
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.BNT162b2 疫苗对 5 至 11 岁儿童中奥密克戎的有效性。
N Engl J Med. 2022 Aug 11;387(6):525-532. doi: 10.1056/NEJMoa2203209. Epub 2022 Jul 20.